

## **Human Papillomavirus (HPV) Vaccination Report: Georgia**

Working Together to Reach National Goals for HPV Vaccination


The Morbidity and Mortality Weekly Report (MMWR)\* recently released the 2015 National Immunization Survey-Teen (NIS-Teen) data, which provides national, state, regional, and selected local area estimates of vaccination coverage. As reported in the MMWR, "In 2015, coverage with each HPV vaccine dose increased among males, however, among females, ≥1 dose HPV vaccination coverage increased only modestly, and no change was observed in coverage with ≥2 and ≥3 HPV doses." As in prior years, coverage with ≥1 HPV vaccine dose was lower than coverage estimates for two other vaccines routinely recommended at age 11–12 years, highlighting ongoing missed opportunities for HPV vaccination when other recommended vaccines are administered. Next year, a revised Healthcare Effectiveness Data and Information Set (HEDIS) measure will be implemented to evaluate receipt of the three recommended vaccines by age 13 years in females and males combined in one composite indicator,\*\* facilitating health plans' and providers' assessment of their performances in administering these vaccines on time

#### 2016 HPV Vaccine Distribution Trends in Georgia

Below are available year-to-date totals of CDC and non-CDC distributed HPV vaccine doses of Gardasil and Gardasil 9 in your state or city. CDC recommends examining vaccine distribution data for trends to approximate recent HPV vaccine administration, as distribution data can inform action in real time to increase vaccination.

to adolescents. See page 2 of this report for 2015 NIS-Teen vaccination coverage, as well as a data summary for Georgia.

# Year-to-date Total of Distributed<sup>†</sup> Gardasil and Gardasil 9 HPV Vaccine Doses in Georgia (2012-2016)



Year-to-Date Total of Distributed<sup>†</sup> Gardasil and Gardasil 9 HPV Vaccine Doses, GA (2015-2016)

aluasii 9 HFV Vaccille Doses, GA (2013-2010)									
	2015	2016	% change						
Jan	17,917	20,763	15.9%						
Feb	32,844	40,216	22.4%						
Mar	52,632	61,534	16.9%						
Apr	72,452	81,244	12.1%						
May	93,748	102,881	9.7%						
Jun	124,993	131,512	5.2%						
Jul	162,781								
Aug	211,654								
Sept	240,227								
Oct	267,195								
Nov	293,618								
Dec	310,671								

<sup>†</sup>These data represent an estimate of all Gardasil and Gardasil 9 HPV vaccine doses distributed in Georgia.

<sup>\*\*</sup>National Committee for Quality Assurance. NCQA updates quality measures for HEDIS® 2017 (press release). Washington, DC: National Committee for Quality Assurance; 2016. <a href="http://www.ncqa.org/newsroom/details/ncqa-updates-quality-measures-for-hedis-2017">http://www.ncqa.org/newsroom/details/ncqa-updates-quality-measures-for-hedis-2017</a>





distributed in the United States, are not included in this report.

<sup>\*</sup>To read the full MMWR about the 2015 NIS-Teen analysis, visit: http://www.cdc.gov/mmwr/volumes/65/wr/mm6533a4.htm?s\_cid=mm6533a4\_e



### **Human Papillomavirus (HPV) Vaccination Report: Georgia**

Working Together to Reach National Goals for HPV Vaccination

September 2016

#### Estimates of Teen Vaccination Coverage Nationwide and in Georgia: 2014-2015


To assess vaccination coverage among teens aged 13–17 years, CDC analyzed the 2015 NIS-Teen survey data collected through questionnaires completed by vaccination providers following consents by interviewed parents or guardians.

#### Estimated National and State/Local Vaccination Coverage, Teens Aged 13-17 Years, NIS-Teen 2014-2015

			HPV						
	≥1 Tdap	≥1 MenACWY	Females			Males			
			≥1 dose	≥2 doses	≥3 doses	≥1 dose	≥2 doses	≥3 doses	
Georgia									
2014	86.1(±4.8)	74.9(±6.1)	65.4(±9.1)	56.3(±9.5)	47.1(±9.7)	41.2(±9.0)	28.0(±7.8)	21.0(±7.2)	
2015	90.2(±4.0)	87.0(±4.6)*	54.4(±9.5)	38.7(±8.9)§	32.3(±8.4) <sup>§</sup>	51.0(±8.5)	42.5(±8.4)*	27.5(±7.6)	
<b>United States</b>									
2014	87.6(±0.9)	79.3(±1.1)	60.0(±1.9)	50.3(±1.9)	39.7(±1.9)	41.7(±1.8)	31.4(±1.7)	21.6(±1.6)	
2015	86.4(±1.0)	81.3(±1.0)*	62.8(±1.8)*	52.2(±1.8)	41.9(±1.8)	49.8(±1.8)*	39.0(±1.7)*	28.1(±1.6)*	

Ref: Reagan-Steiner et al. National, Regional, State, and Selected Local Area Vaccination Coverage among Adolescents Aged 13–17 Years: United States, 2015. Morbidity and Mortality Weekly Report (MMWR). August 26, 2016.

#### Estimated Vaccination Coverage Among Adolescents Aged 13-17 Years, Georgia, NIS-Teen, 2008-2015



NIS-Teen estimates from 2008–2013 connected with dashed lines are previously published estimates using the previous adequate provider data (APD) definition. NIS-Teen estimates from 2013–2015 connected with solid lines use the revised APD definition. For complete footnotes, consult the MMWR article:

http://www.cdc.gov/mmwr/volumes/65/wr/mm6533a4.htm?s cid=mm6533a4 e

#### 2015 NIS-Teen HPV Data Summary: Georgia

Compared to estimates from 2014, HPV vaccination coverage in Georgia:

- Significantly decreased from 2014 to 2015 in ≥2 and ≥3 dose coverage for females. There was a non-significant decrease in ≥1 dose coverage among females.
- Significantly increased from 2014 to 2015 in ≥2 dose coverage for males. There were non-significant increases in ≥1 and ≥3 dose coverage among males.

Consult this CDC-authored publication for information on interpreting survey findings:

http://www.sciencedirect.com/science/article/pii/S0749379701002756

#### **Resources to Increase HPV Vaccination Coverage**

- Get involved with partners, such as the American Cancer Society (ACS). Information on the National HPV Vaccination Roundtable can be found at: <a href="http://www.cancer.org/healthy/informationforhealthca">http://www.cancer.org/healthy/informationforhealthca</a> reprofessionals/nationalhpvvaccinationroundtable/
- View the latest #PreteenVaxScene webinar, "Research Project Update: AFIX Program Strategies for Improving HPV Vaccination Rates in the Field":

https://www.youtube.com/watch?v=MAF3 Mt7zdQ

 Visit TeenVaxView for comprehensive interactive adolescent vaccination coverage data online at: <a href="https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/index.html">https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/index.html</a>





Abbreviations: Tdap= tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; MenACWY= quadrivalent meningococcal conjugate vaccine.

Tdap, MenACWY, and HPV vaccines are recommended for adolescents aged 11–12 years.

<sup>\*</sup>Statistically significant (p<0.05) increase from 2014 estimates.

<sup>§</sup>Statistically significant (p<0.05) decrease from 2014 estimates.